Join us on Friday, April 30, at 7:30 p.m. EDT for our Annual Gala. It’s free and will be fun, great items up for auction! <<Learn more here>> 

Clinical Trials

Clinical trials are research studies that test new potential treatments for a disease. Talk to your doctor about possible clinical trials that could be helpful to you.

hepbfoundation hepdelta banner 3

Glossary: HBV = Hepatitis B, CHB = Chronic hepatitis B, HDV = Hepatitis D, CHD = Chronic hepatitis D, ALT = Alanine aminotransferase, AST = Aspartate aminotransferase, EOT = End of Treatment, NTCP = Sodium/taurocholate cotransporting polypeptide, LNF-containing regimens = Lonafarnib-containing regimens

Recruiting - A Study of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-Infected with Hepatitis B and Hepatitis Delta Virus

JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection designed to treat chronic hepatitis B virus (HBV) infection via ribonucleic acid interference mechanism. This phase 2 study is designed to evaluate safety and efficacy of JNJ-73763989 in HBV-infected patients who are co-infected with HDV. The study consists of 2 parts: Part 1 will evaluate safety, tolerability and antiviral activity of JNJ-73763989 + NA while Part 2 will evaluate the safety and efficacy of the JNJ-73763989 + NA regimen in the treatment of HBV/HDV co-infection. Each part includes 3 phases: Screening phase (from 4 Week up to maximum of 8 weeks), Intervention phase (144 Week for Arm A and 148 Week for Arm B) and Follow-up phase (48 Week). The duration of individual study participation will be between 196 and 204 weeks. Contact 844.434.4210 or for more information and refer to identifier NCT04535544.

Currently recruiting patients in:

United States

  • California, Maryland, Massachusetts, New Jersey


  • Australia, Brazil, China, France, Germany, Italy, Japan, New Zealand, Russian Federation, Spain, Sweden, Taiwan, Turkey, United Kingdom


Recruiting - Phase 3 Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon-Alfa-2a (D-LIVR) - U.S. and International

Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and ALT normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline. Contact: Sue Speyer 650-272-6138 or and refer to identifier NCT03719313. Also visit for more information. 

Currently recruiting patients in:

United States

  • California, Connecticut, Florida, Illinois, Iowa, Maryland, Michigan, New York, Oklahoma, Texas


  • Belguim, Bulgaria, Canada, France, Germany, Greece, Israel, Italy, Republic of Moldova, Mongolia, New Zealand, Pakistan, Romania, Russia, Spain, Sweden, Switzerland, Taiwan, Turkey, UK 

Active, Not Currently Recruiting - Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide (Hepcludex) in Patients With Chronic Hepatitis Delta - International

This study is designed to assess the long-term efficacy and safety of Bulevirtide in patients with HDV. 

Active, Not Currently Recruiting - Phase 2b Study of Bulevirtide (With Peginterferon Alfa-2a) in Patients With Chronic Hepatitis Delta - International

A Multicenter, Open-label, Randomized Phase 2b Clinical Study. 

Recruiting - The Hepatitis Delta International Network - International

Multicenter, observational study (patients will not receive any treatment) that will build a registry of HDV patients around the world and collect clinical information. Contact: Dr. Heiner Wedemeyer at or Dr. Petra Doerge at and refer to identifier NCT02375906.

Currently recruiting patients in: 

  • Austria
  • Belgium
  • Brazil
  • Georgia
  • Germany
  • Greece
  • Italy
  • Republic of Moldova
  • Pakistan
  • Romania
  • Spain
  • Vietnam

May Still Be Recruiting - Phase 2 Study of Ezetimibe for Patients With Chronic Hepatitis Delta – International

Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry, that include two hydrophobes and one hydrogen bond acceptor. Therapy with ezetimibe may lead to decline in HDV levels. The aim of the study is to evaluate the utility of ezetimibe in patients with CHD. Contact: Zaigham Abbas at 922135862937 or email and refer to identifier NCT03099278.

Currently recruiting patients in:

  • Sindh, Pakistan

Recruiting - Evaluation of Patients with Liver Disease, Including Hepatitis Delta – U.S.

Evaluate, investigate and follow-up with patients suffering from acute and chronic liver disease. Qualified patients may be able to participate in other offered studies. Contact Patricia E. Alcivar at 301-435-6121/ or Dr. T. Jake Liang at 301-496-1721/ and refer to identifier NCT00001971.

Currently recruiting patients in:

  • Bethesda, Maryland (National Institute of Health)

 Active, Not Recruiting - Hepatitis B Research Network Adult Cohort Study (HBRN) - U.S. and Canada

The primary purpose of this study is to describe participants with hepatitis B virus (HBV) infection and identify factors that may cause the disease to activate or worsen. This study includes people who also have hepatitis delta or have tested positive for the hepatitis delta antibody. This is an observational study where no treatment will be administered.

Clinical Trial Process

Clinical Trial Process FlowChart

Learn more about all current hepatitis delta clinical trials.

Additional Resources is a service of the National Institutes of Health that provides a list of all the clinical trials that are being carried out in the United States and abroad. You can search for a clinical trial by disease, drug therapy, or trial location. offers a free search service by the Center for Information and Study on Clinical Research Participation (CISCRP) to help you find a clinical trial that may be right for you.

Hepatitis B Clinical Trials Page is a list that is updated each month by the Hepatitis B Foundation of clinical trials specific for hepatitis B.

Updated December 2020